HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prostanoid receptor expression in colorectal cancer related to tumor stage, differentiation and progression.

AbstractINTRODUCTION:
Alterations in eicosanoid metabolism is well established in a variety of malignant tumors, particularly colorectal carcinoma. Recent studies in our laboratory have emphasized a role for EP subtype receptors in progression of colorectal cancer and disease specific mortality. Therefore, the aim of the present study was to extend our knowledge to include additional receptor expression (DP1, DP2, FP, IP, TP) for prostanoids (PGD2, TXA2, PGF2alpha, PGI2) in relationship to tumor stage, differentiation and progression of colorectal cancer.
MATERIAL AND METHODS:
Total RNA from 62 tumors and adjacent normal colon tissue (n = 48) was extracted. Quantification of receptor expression was performed by realtime PCR and related to the expression of an appropriate housekeeping gene (GAPDH). Tumors were assessed according to Dukes A-D (stage I-IV).
RESULTS:
DP1, DP2, FP and IP receptor subtypes displayed significantly reduced overall expression in tumor tissue compared to normal colon tissue, while the TP receptor subtype showed significantly higher expression in tumor tissue. Overall expression of the prostanoid receptors in tumor tissue was not related to clinical indexes as tumor stage and tumor cell differentiation evaluated by multivariate analyses. Cultured colorectal cancer cell lines with low (HT-29) and high (HCA-7) intrinsic PGE2 production at confluent state did not express DP1 and IP receptor subtypes, but displayed low expression of DP2, FP and TP receptor subtypes.
CONCLUSION:
The results in the present study indicate imbalanced expression of prostanoid receptors in colorectal cancer compared to normal colon tissue without clear cut relationship to disease progression. Therefore, future studies should be performed on defined cells within the tumor tissue compartment determining whether any prostanoid receptor(s) is useful as a molecular target in treatment or prevention of colorectal cancer.
AuthorsAnnika Gustafsson, Elisabeth Hansson, Ulf Kressner, Svante Nordgren, Marianne Andersson, Christina Lönnroth, Kent Lundholm
JournalActa oncologica (Stockholm, Sweden) (Acta Oncol) Vol. 46 Issue 8 Pg. 1107-12 ( 2007) ISSN: 0284-186X [Print] England
PMID17943472 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • PTGIR protein, human
  • Receptors, Epoprostenol
  • Receptors, Immunologic
  • Receptors, Prostaglandin
  • Receptors, Thromboxane
  • prostaglandin F2alpha receptor
  • prostanoid D receptor 1, human
  • prostaglandin D2 receptor
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma (genetics, pathology)
  • Cell Differentiation (genetics)
  • Colorectal Neoplasms (genetics, pathology)
  • Disease Progression
  • Female
  • Gene Expression Regulation, Neoplastic
  • HT29 Cells
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Receptors, Epoprostenol
  • Receptors, Immunologic (genetics)
  • Receptors, Prostaglandin (genetics)
  • Receptors, Thromboxane (genetics)
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: